Spindletop Capital

Investment decisions are led by the managing directors: Dr. Evan Melrose, Steve Whitlock, Dr. Kelly Huang, Shannon Rothschild, and Jim Henry. The late Stephen Hipp was a managing director until his passing in 2023. The firm does not publicly designate a single CIO or CEO; authority appears distributed across the managing director group, supported by an operating partner and business and scientific advisors.

No. Spindletop explicitly targets commercial-stage and profitable healthcare businesses where technical, regulatory, and commercial risks have been largely mitigated. The firm pursues a venture growth capital strategy — expansion capital, buyouts, and corporate spin-outs — rather than seed or Series A investments in pre-revenue biotech or medtech startups.

Spindletop is diversified across healthcare sectors including medical devices, molecular diagnostics, specialty pharmaceuticals, digital health, physician practice management, and tech-enabled services. Portfolio examples include Sanova Dermatology (physician practice management), Bioventus (medical devices), Castle Biosciences (molecular diagnostics), and Navigating Cancer (digital health).

Spindletop cites deep Texas resources and research institutions as a proprietary advantage for sourcing healthcare opportunities nationwide. The firm also emphasizes relationships with entrepreneurs and syndicate investment partners, positioning itself as a sought-after co-investor due to industry and financial expertise. Specific institutional partners and sourcing channels beyond Texas are not publicly detailed.

The firm's website describes Spindletop as a "national fund" but does not disclose fund structures, vintages, or whether it has raised multiple vehicles. The offering includes direct equity, co-investment, direct secondaries, and management buyouts. Absent public fund documentation, the exact vehicle architecture remains undisclosed.

Spindletop prominently references "family office heritage" on its website and aligns its philosophy with ILPA principles, suggesting roots in managing capital for a single-family source. However, the specific family, wealth origin, and whether family capital remains a meaningful component of the fund's LP base are not publicly disclosed.

Spindletop's values include generosity, stating that financial success provides benefits for academic institutions, communities, and patients. The firm's website does not list a separate foundation or philanthropic vehicle, and no public filings confirm a structured charitable entity tied to Spindletop.